Certificate of Suitability (CEP) and compliance with European Pharmacopoeia MCQs With Answer

Introduction

Understanding the Certificate of Suitability (CEP) and compliance with the European Pharmacopoeia is essential for M.Pharm students preparing for regulatory roles. A CEP is an EDQM-issued document that confirms an active substance meets the quality requirements of the European Pharmacopoeia, streamlining regulatory review across Europe. This blog presents focused multiple-choice questions covering CEP purpose, dossier content, procedural benefits, interactions with marketing authorisation holders, variations, inspections and practical implications for drug development and quality assurance. These MCQs will help you deepen technical knowledge, prepare for exams, and appreciate how CEPs reduce duplicative documentation while ensuring patient safety through harmonised quality standards.

Q1. What is a Certificate of Suitability (CEP) in the context of European regulatory practice?

• A certificate issued by EDQM confirming that an active substance’s quality can be controlled by the European Pharmacopoeia monograph
• A marketing authorisation for finished medicinal products in the EU
• A national GMP certificate for manufacturing sites
• A clinical trial approval document

Correct Answer: A certificate issued by EDQM confirming that an active substance’s quality can be controlled by the European Pharmacopoeia monograph

Q2. Which organisation is responsible for issuing CEPs?

• European Medicines Agency (EMA)
• European Directorate for the Quality of Medicines & HealthCare (EDQM)
• European Commission
• World Health Organization (WHO)

Correct Answer: European Directorate for the Quality of Medicines & HealthCare (EDQM)

Q3. A CEP certifies compliance primarily with which pharmacopoeial standard?

• United States Pharmacopeia (USP)
• British Pharmacopoeia (BP)
• European Pharmacopoeia (Ph. Eur.)
• Japanese Pharmacopoeia (JP)

Correct Answer: European Pharmacopoeia (Ph. Eur.)

Q4. What is the main regulatory benefit of a CEP for a marketing authorisation holder (MAH)?

• Exempts the product from all quality testing
• Facilitates assessment by reducing the need to submit full active substance documentation to each EU authority
• Automatically grants GMP compliance for the manufacturing site
• Provides a marketing authorisation valid worldwide

Correct Answer: Facilitates assessment by reducing the need to submit full active substance documentation to each EU authority

Q5. Which dossier type is commonly replaced or simplified by submitting a CEP?

• Clinical study report
• Active Substance Master File (ASMF) / Drug Master File (DMF)
• Marketing Authorisation Application (MAA)
• Pharmacovigilance System Master File (PSMF)

Correct Answer: Active Substance Master File (ASMF) / Drug Master File (DMF)

Q6. Which of the following is typically included in the CEP documentation?

• Full commercial sales and pricing history
• Specifications, analytical procedures and control strategy demonstrating compliance with the relevant Ph. Eur. monograph
• Detailed clinical efficacy data
• Packaging artwork and patient leaflet

Correct Answer: Specifications, analytical procedures and control strategy demonstrating compliance with the relevant Ph. Eur. monograph

Q7. Which EDQM unit performs the technical assessment of CEP applications?

• European Medicines Agency assessment teams
• EDQM Certification Department (Certification and Ph. Eur. Secretariat)
• National competent authorities of each EU country
• World Health Organization inspection unit

Correct Answer: EDQM Certification Department (Certification and Ph. Eur. Secretariat)

Q8. What is the typical validity status of a granted CEP?

• Valid for five years and then automatically expires
• Valid indefinitely unless revised, suspended or withdrawn by EDQM
• Valid for one year and renewable annually
• Automatically invalid after a change to the product

Correct Answer: Valid indefinitely unless revised, suspended or withdrawn by EDQM

Q9. Who is responsible for notifying EDQM about changes that may affect an issued CEP?

• The national competent authority of the MAH
• The CEP holder (applicant/manufacturer)
• The finished product marketing authorisation holder only
• The European Commission

Correct Answer: The CEP holder (applicant/manufacturer)

Q10. A CEP typically provides assurance about which quality attribute of an active substance?

• Clinical safety profile in patients
• Compliance with impurity limits and analytical specifications as per the Ph. Eur. monograph
• Packaging stability under real use conditions
• Marketing exclusivity period

Correct Answer: Compliance with impurity limits and analytical specifications as per the Ph. Eur. monograph

Q11. Can a CEP be granted for an active substance that has no specific Ph. Eur. monograph?

• No — CEPs are normally issued for substances covered by a Ph. Eur. monograph
• Yes — for any substance regardless of monograph status
• Only if the MAH requests it from EMA
• Yes — but only for excipients, not active substances

Correct Answer: No — CEPs are normally issued for substances covered by a Ph. Eur. monograph

Q12. What reference material is typically used to verify analytical methods in the context of Ph. Eur. compliance?

• United States Pharmacopeia Reference Standards
• European Pharmacopoeia Reference Standards
• In-house commercial reference materials only
• WHO International Nonproprietary Names (INN)

Correct Answer: European Pharmacopoeia Reference Standards

Q13. If a CEP indicates compliance with the Ph. Eur., does the finished product MAH still need to include an active substance specification in the MAA?

• No — the CEP replaces all specification requirements in the MAA
• Yes — the MAH must include finished product specifications and may reference the CEP for active substance quality
• Only for biologics is this required
• Only stability data are required, not specifications

Correct Answer: Yes — the MAH must include finished product specifications and may reference the CEP for active substance quality

Q14. Who safeguards commercially confidential information submitted in a CEP dossier when the CEP is published?

• EDQM, which can redact confidential data on request of the applicant
• The national competent authority of the MAH only
• The marketing authorisation holder must publish all information publicly
• Confidentiality is not permitted; all data become public

Correct Answer: EDQM, which can redact confidential data on request of the applicant

Q15. Which organisation has the authority to withdraw or suspend an issued CEP?

• European Medicines Agency (EMA)
• EDQM
• Individual national competent authorities acting alone
• World Health Organization (WHO)

Correct Answer: EDQM

Q16. If a manufacturer changes an analytical method for the active substance after a CEP has been issued, what is the correct regulatory step?

• No action is required — changes are allowed without notification
• Notify EDQM and submit data to obtain a revised CEP or approval of the change
• Only inform the finished product MAH; EDQM need not be informed
• Immediately withdraw the CEP and reapply

Correct Answer: Notify EDQM and submit data to obtain a revised CEP or approval of the change

Q17. Does holding a CEP imply automatic GMP compliance for the manufacturing site of the active substance?

• Yes — CEP confirms both quality and GMP compliance
• No — GMP compliance is assessed separately by competent authorities and requires inspections
• Yes, but only for EU-based manufacturers
• Only if the CEP explicitly states GMP certification

Correct Answer: No — GMP compliance is assessed separately by competent authorities and requires inspections

Q18. Which type of data is typically submitted as supportive evidence in a CEP dossier?

• Representative batch analytical results and method validation summaries
• Full clinical trial raw data
• Marketing and sales forecasts
• Patient-level pharmacovigilance reports

Correct Answer: Representative batch analytical results and method validation summaries

Q19. How does EDQM verify that the information presented in a CEP dossier corresponds to the actual manufacturing practice?

• EDQM performs dossier assessment and may require on-site inspections or rely on existing GMP certificates and national inspections
• EDQM only performs a paper check and never requests inspections
• The MAH is solely responsible and no verification is performed
• Verification is performed exclusively by WHO auditors

Correct Answer: EDQM performs dossier assessment and may require on-site inspections or rely on existing GMP certificates and national inspections

Q20. If the European Pharmacopoeia monograph for an active substance is revised after a CEP has been granted, what is the expected course of action?

• The CEP remains unchanged and no action is necessary
• The CEP holder must provide data or request revision so the CEP can be updated to demonstrate continued compliance with the revised monograph
• The CEP is automatically revoked and the product must be withdrawn
• No action is required unless national authorities request it

Correct Answer: The CEP holder must provide data or request revision so the CEP can be updated to demonstrate continued compliance with the revised monograph

Download